ACVR1 is a key bone morphogenetic protein (BMP) type I receptor involved in regulating osteogenesis and bone remodeling. By targeting and inhibiting ACVR1 signaling, prafnosbart aims to modulate the BMP pathway, potentially promoting bone formation, increasing bone mineral density, and restoring normal bone turnover. Its development is particularly relevant for conditions characterized by impaired bone formation or excessive bone loss, such as certain types of osteoporosis or fibrous dysplasia.